Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA3 | P07451 | 5/20 | 0.42 |
| ▸ | CA4 | P22748 | 5/20 | 0.42 |
| ▸ | CA6 | P23280 | 5/20 | 0.42 |
| ▸ | CA5A | P35218 | 5/20 | 0.42 |
| ▸ | CA7 | P43166 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 5/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.42 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10115540 | 0.83 | PKM (0.61) | CA1CA2KMT2AHSD17B10 | |
| SCHEMBL10113907 | 0.79 | HDAC1 (0.64) | KMT2A | |
| SCHEMBL10115401 | 0.79 | HDAC1 (0.53) | — | |
| SCHEMBL10113751 | 0.73 | ALDH1A1 (0.50) | KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL10115440 | 0.70 | GRIA1 (0.47) | GRIA1ALDH1A1 | |
| SCHEMBL10113688 | 0.69 | HDAC3 (0.56) | KMT2AGRIA1ALDH1A1 | |
| SCHEMBL10115499 | 0.69 | GRIA1 (0.46) | KMT2AGRIA1ALDH1A1 | |
| SCHEMBL10115442 | 0.69 | GRIA1 (0.46) | GRIA1ALDH1A1 | |
| SCHEMBL10115297 | 0.69 | HDAC6 (0.67) | ALDH1A1 | |
| SCHEMBL10115503 | 0.68 | ALDH1A1 (0.49) | GRIA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | GLS 2329/4885CA12 1954/4885CA1 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.